Home/IMUNON/Jeffrey W. Church
JW

Jeffrey W. Church

Interim Chief Financial Officer

IMUNON

IMUNON Pipeline

DrugIndicationPhase
IMNN-001 (TheraPlas™-IL-12)Advanced Ovarian Cancer (Epithelial Ovarian Cancer)Phase 2
PlaCCine PlatformInfectious Diseases (SARS-CoV-2 validation)Pre-clinical